Scope:
Specific challenge: The Global Alliance for Chronic Diseases will focus its 2015 call for implementation science proposals on lung diseases.
With the burden of this chronic non-communicable disease ever-increasing, the Global Alliance for Chronic Diseases (GACD[1]), of which the Commission is a member, has agreed to launch a call for proposals on the prevention and treatment of lung diseases, with a focus on intervention research in low- and middle-income countries (LMIC) and/or in vulnerable populations in high income countries (HIC).
Controlling tobacco consumption and reducing harmful environmental exposures (indoor and outdoor exposures) are among the most important interventions in lung disease[2].
Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide[3]. Tobacco addiction causes about 5.4 million people death each year, and if resolute and urgent action is not taken by 2030 the epidemic will cause between 8 and 10 million deaths each year, of which over 80% occur in low- and middle-income countries (LMIC). Smoking is a major cause of inequality in health between gender, socioeconomic groups and age categories. With nicotine being highly addictive, it is important to prevent young people from taking up tobacco use. 70% of the smokers start before the age of 18 and 94% before the age of 25 years.
The precise health risk that environment exposure poses to lung diseases is not well established because of the difficulty to assess the prevalence linked to the amount of exposure. Risk assessment is further complicated by socioeconomic, age and genetic factors.
Scope: Proposals must focus on lung diseases and they must have an implementation science focus. They must address what works, for whom, under what contextual circumstances and are the intervention(s) adaptable and scalable in ways that are accessible and equitable. Proposals should generate new knowledge on interventions and their implementation for the prevention and treatment of lung diseases in LMIC, and/or in vulnerable populations in HIC[4]. Proposals must focus on existing approaches to prevention and control of lung diseases or develop treatments at lower costs. They should demonstrate a sound understanding of the local health system context as well as the global cross-sectorial context.
All proposals should:
− Local and/or national policy makers will be engaged both at the start of the project as well as the end.
− The project outcomes/evidence will be utilised for the scaling up of the intervention on a local, national and international level.
− Future scaled-up implementations will fit within the local social, cultural and economic context.
− Identify obstacles such as inequities and equity gaps including gender that will be taken into account in the design of an implementation strategy.
Proposals may focus on a wide range of prevention and/or treatment strategies. This may include programmes addressing (one of or combinations of):
The GACD aims to develop a network of researchers that can enhance cumulative learning across individual projects, and work towards understanding how socio-economic, cultural, geopolitical and policy contexts have influenced results and how findings might be adapted and applied in different settings. The funded researchers should meet annually to discuss their research and share information and data in order to develop approaches to standardise data collection, and wherever feasible to use these standardised approaches in their respective projects.
The Commission considers that proposals requesting a contribution from the EU of between EUR 1 to 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected impact:
Type of action: Research and innovation actions
[1] http://www.gacd.org/
[2] The World Health Report 2002—Reducing Risks, Promoting Healthy Life (http://www.who.int/whr/2002/en/)
[3] WHO, Priority Medicine for Europe and the World 2013 Update (http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf)
[4] The applicant needs to explain why the proposed population under investigation in HIC is vulnerable
[5] Cigarettes, slim cigarettes, water pipes, smokeless tobacco, novel tobacco products.
[6] As defined in Article 2(16) of the Tobacco Products Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014, 'electronic cigarette' means a product that can be used for consumption of nicotine-containing vapour via a mouth piece, or any component of that product, including a cartridge, a tank and the device without cartridge or tank. Electronic cigarettes can be disposable or refillable by means of a refill container and a tank, or rechargeable with single use cartridges
[7] http://www.un.org/millenniumgoals/bkgd.shtml